Please login to the form below

Not currently logged in
Email:
Password:

NMOSD

This page shows the latest NMOSD news and features for those working in and with pharma, biotech and healthcare.

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition

Viela's portfolio of assets includes FDA-approved NMOSD therapy Uplizna. Horizon Therapeutics has entered into a definitive agreement to acquire Viela Bio for $3bn, in an effort to strengthen its ... Currently, Viela has one US Food and Drug

Latest news

More from news
Approximately 5 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...